The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review.


Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 16 09 2019
accepted: 15 11 2019
pubmed: 17 3 2020
medline: 20 2 2021
entrez: 17 3 2020
Statut: ppublish

Résumé

The therapeutic management of cancers has undergone considerable changes due to the emergence of genomics tools and tumor molecular deciphering. In this context, a dual pharmacological approach based on pharmacogenomic analyses and therapeutic drug monitoring is now part of the routine care in cancer management for personalized therapies. First, molecular and immune profiling of tumors allows the emergence of new pharmacological targets in common as well as in rare cancers. Second, pharmacogenomic analyses coupled to therapeutic drug monitoring guide the prescription by adjusting regimen and managing drug resistance.

Identifiants

pubmed: 32173061
pii: S0040-5957(20)30015-9
doi: 10.1016/j.therap.2020.02.010
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-193

Informations de copyright

Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Baptiste Louveau (B)

Department of pharmacology and tumor genomics, Saint-Louis hospital, Assistance publique-Hôpitaux de Paris, 75010 Paris, France; Université de Paris, INSERM UMRS 976, 75010 Paris, France.

Fanélie Jouenne (F)

Department of pharmacology and tumor genomics, Saint-Louis hospital, Assistance publique-Hôpitaux de Paris, 75010 Paris, France; Université de Paris, INSERM UMRS 976, 75010 Paris, France.

Florentia Kaguelidou (F)

Department of pediatric pharmacology and pharmacogenetics, Robert-Debré hospital, Assistance publique-Hôpitaux de Paris, 75019 Paris, France; INSERM, CIC 1426, 75019 Paris, France.

Alexandra Landras (A)

Université de Paris, INSERM UMRS 976, 75010 Paris, France.

Lauriane Goldwirt (L)

Department of pharmacology and tumor genomics, Saint-Louis hospital, Assistance publique-Hôpitaux de Paris, 75010 Paris, France; Université de Paris, INSERM UMRS 976, 75010 Paris, France.

Samia Mourah (S)

Department of pharmacology and tumor genomics, Saint-Louis hospital, Assistance publique-Hôpitaux de Paris, 75010 Paris, France; Université de Paris, INSERM UMRS 976, 75010 Paris, France. Electronic address: samia.mourah@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH